Dolutegravir in Pregnancy as Compared with Current HIV Regimens in the United States

Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial

(2021) Shahin Lockman et al.   LANCET

Mother-to-Child HIV Transmission with in utero Dolutegravir vs. Efavirenz in Botswana

(2020) Sonya Davey et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): an open-label, randomised controlled trial

(2020) Kenneth Kintu et al.   Lancet HIV

Risk of birth defects and perinatal outcomes in HIV-infected women exposed to integrase strand inhibitors during pregnancy

(2020) Jeanne Sibiude et al.   AIDS

Neural-Tube Defects and Antiretroviral Treatment Regimens in Botswana

(2019) Rebecca Zash et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study)

(2019) Catriona Waitt et al.   PLOS MEDICINE

Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study

(2018) Rebecca Zash et al.   Lancet Global Health

Neural-Tube Defects with Dolutegravir Treatment from the Time of Conception

(2018) Rebecca Zash et al.   NEW ENGLAND JOURNAL OF MEDICINE

Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study

(2017) Catherine Orrell et al.   Lancet HIV

Timing of initiation of antiretroviral therapy and adverse pregnancy outcomes: a systematic review and meta-analysis

(2017) Olalekan A Uthman et al.   Lancet HIV

Surveillance monitoring for safety of in utero antiretroviral therapy exposures: current strategies and challenges

(2016) Rebecca M. Zash et al.   Expert Opinion On Drug Safety

The PHACS SMARTT Study: Assessment of the Safety of In Utero Exposure to Antiretroviral Drugs

(2016) Russell B. Van Dyke et al.   Frontiers in Immunology

Brief Report

(2015) Sharon Walmsley et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study

(2015) Jean-Michel Molina et al.   Lancet HIV

Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study

(2014) Bonaventura Clotet et al.   LANCET

Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naïve HIV-1-positive individuals: 96 week results from FLAMINGO

(2014) Jean-Michel Molina et al.   Journal of the International AIDS Society

Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial

(2013) François Raffi et al.   LANCET INFECTIOUS DISEASES

Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection

(2013) Sharon L. Walmsley et al.   NEW ENGLAND JOURNAL OF MEDICINE

New Intrauterine Growth Curves Based on United States Data

(2010) I. E. Olsen et al.   PEDIATRICS

Race, Racism, and Racial Disparities in Adverse Birth Outcomes

(2008) TYAN PARKER DOMINGUEZ   CLINICAL OBSTETRICS AND GYNECOLOGY